Novartis AG
NVS
$125.50
$0.490.39%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.47% | 12.32% | 11.87% | 15.14% | 8.84% |
| Total Other Revenue | 28.65% | 117.22% | 32.99% | 14.73% | 12.58% |
| Total Revenue | 9.00% | 15.26% | 12.38% | 15.13% | 8.93% |
| Cost of Revenue | 9.31% | 4.60% | 4.13% | 28.95% | 3.75% |
| Gross Profit | 8.91% | 18.74% | 15.20% | 11.28% | 10.73% |
| SG&A Expenses | 5.42% | 11.32% | 7.64% | 2.49% | 1.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -91.00% | -101.56% | -60.43% | 123.43% | 165.53% |
| Total Operating Expenses | 2.46% | 5.46% | 0.78% | 66.21% | -8.52% |
| Operating Income | 26.17% | 37.11% | 42.25% | -33.03% | 118.13% |
| Income Before Tax | 23.96% | 17.96% | 40.84% | 38.20% | 118.11% |
| Income Tax Expenses | 33.00% | -14.79% | 80.95% | 278.16% | 412.82% |
| Earnings from Continuing Operations | 23.39% | 23.97% | 34.26% | 6.90% | 110.51% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -150.00% | -- | -- | -- | 300.00% |
| Net Income | 23.17% | 24.49% | 34.15% | -66.77% | 81.09% |
| EBIT | 26.17% | 37.11% | 42.25% | -33.03% | 118.13% |
| EBITDA | 22.14% | 30.08% | 31.77% | -41.81% | 62.03% |
| EPS Basic | 28.68% | 29.92% | 39.33% | -65.72% | 85.60% |
| Normalized Basic EPS | 31.87% | 41.99% | 51.54% | -31.08% | 139.77% |
| EPS Diluted | 28.66% | 29.56% | 38.93% | -65.63% | 84.60% |
| Normalized Diluted EPS | 31.88% | 42.02% | 51.60% | -31.16% | 139.47% |
| Average Basic Shares Outstanding | -4.27% | -4.18% | -3.72% | -3.07% | -2.42% |
| Average Diluted Shares Outstanding | -4.29% | -4.20% | -3.75% | -2.95% | -2.31% |
| Dividend Per Share | -- | -- | -- | -1.44% | -- |
| Payout Ratio | -- | -0.17% | -0.24% | -- | -- |